Annie Hubert, Senior Director, EU Section & Public Policy for the Alliance for Regenerative Medicine (ARM) describes some of the issues that companies in the advanced therapies field are facing in terms of market access and stakeholder education in Europe, as well as some of the key breakthroughs that European companies have made in this dynamic sector.
Could you begin by giving us a short introduction to your background?
"Market access is a big priority for the organization as a whole and this is also true in Europe."
